Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12N-015/01
C12N-015/06
출원번호
US-0786530
(2010-05-25)
등록번호
US-8445229
(2013-05-21)
발명자
/ 주소
Grasso, Luigi
Liang, Shaohong
Nicolaides, Nicholas C.
Sass, Philip M.
출원인 / 주소
Morphotek, Inc.
대리인 / 주소
Woodcock Washburn, LLP
인용정보
피인용 횟수 :
0인용 특허 :
174
초록▼
The invention provides methods for generating high titers of high-affinity antibodies from hybridoma cells produced by fusing myeloma cells with in vitro immunized donor cells. The hybridoma cells or mammalian expression cells with cloned antibody genes from the hybridomas producing the high-affinit
The invention provides methods for generating high titers of high-affinity antibodies from hybridoma cells produced by fusing myeloma cells with in vitro immunized donor cells. The hybridoma cells or mammalian expression cells with cloned antibody genes from the hybridomas producing the high-affinity antibodies may be mismatch repair defective due to defects of endogenous mismatch repair subunits of through expression of a dominant negative allele of a mismatch repair gene which allows the hybridoma cell to be hypermutable, may be rendered hypermutable by chemical means, or may be naturally mismatch repair deficient. High-affinity antibodies and high titer producer cells producing antibodies may be prepared by the methods of the invention.
대표청구항▼
1. A method for producing hybridoma cells producing high-affinity antibodies from in vitro immunized immunoglobulin-producing cells comprising: (a) combining donor cells comprising immunoglobulin-producing cells with an immunogenic antigen in vitro;(b) fusing said immunoglobulin-producing cells with
1. A method for producing hybridoma cells producing high-affinity antibodies from in vitro immunized immunoglobulin-producing cells comprising: (a) combining donor cells comprising immunoglobulin-producing cells with an immunogenic antigen in vitro;(b) fusing said immunoglobulin-producing cells with myeloma cells to form parental hybridoma cells, wherein said hybridoma cells express a dominant negative allele of a mismatch repair gene;(c) incubating said parental hybridoma cells with a chemical mutagen;(d) incubating said parental hybridoma cells to allow for mutagenesis, thereby forming hypermutated hybridoma cells;(e) performing a screen for binding of antibodies to antigen for antibodies produced from said hypermutated hybridoma cells; and(f) selecting hypermutated hybridoma cells that produce antibodies with greater affinity for said antigen than antibodies produced by said parental hybridoma cells;thereby producing hybridoma cells producing high-affinity antibodies. 2. The method of claim 1 wherein said dominant negative allele of a mismatch repair gene comprises a dominant negative allele of a gene selected from the group consisting of PMS2, PMS1, PMSR3, PMSR2, PMSR6, MLH1, GTBP, MSH3, MSH2, MLH3, or MSH1, and homologs of PMSR genes. 3. The method of claim 1 wherein said dominant negative allele of a mismatch repair gene comprises a dominant negative allele of a PMS2 gene. 4. The method of claim 1 further comprising a screen for hypermutated hybridomas that also produce antibodies in higher titers than said parental hybridomas. 5. The method of claim 1 further comprising inactivation of said dominant negative allele of said mismatch repair gene, thereby stabilizing the genome of said hypermutated hybridoma. 6. The method of claim 4 further comprising inactivation of said dominant negative allele of said mismatch repair gene, thereby stabilizing the genome of said hypermutated hybridoma. 7. The method of claim 1 wherein said high affinity antibodies have an affinity of at least about 1×107 M−1 to about 1×1014 M−1. 8. The method of claim 4 wherein said higher titer of said antibodies is at least about 1.5-8 fold greater than the titer produced by said parental hybridoma cell. 9. The method of claim 1 further comprising the step of inactivating said dominant negative allele of a mismatch repair gene by knocking out said dominant negative allele or removing an inducer of said dominant negative allele. 10. The method of claim 1 wherein the dominant negative mismatch repair gene is introduced into said hybridoma cell after the fusion of said myeloma with said immunoglobulin-producing cells. 11. The method of claim 1 wherein said myeloma cells express a dominant negative mismatch repair gene which is also expressed in said hybridoma cells. 12. The method of claim 4 further comprising the step of inactivating said dominant negative allele of a mismatch repair gene by knocking out said dominant negative allele or removing an inducer of said dominant negative allele. 13. A method for producing hybridoma cells that produce high titers of antibodies from in vitro immunized immunoglobulin-producing cells comprising: (a) combining donor cells comprising immunoglobulin-producing cells with an immunogenic antigen in vitro;(b) fusing said immunoglobulin-producing cells with myeloma cells to form parental hybridoma cells, wherein said hybridoma cells express a dominant negative allele of a mismatch repair gene;(c) incubating said parental hybridoma cells with a chemical mutagen;(d) incubating said parental hybridoma cells to allow for mutagenesis, thereby forming hypermutated hybridoma cells;(e) performing a screen of said hypermutated hybridoma cells for antibodies produced in higher titers than that produced by said parental hybridoma cells; and(f) selecting hypermutated hybridoma cells that produce higher titers of antibodies than that produced by said parental hybridoma cells;thereby producing hybridoma cells that produce high titers of antibodies. 14. The method of claim 13 wherein said dominant negative allele of a mismatch repair gene is selected from the group consisting of a dominant negative allele of PMS2, PMS1, PMSR3, PMSR2, PMSR6, MLH1, GTBP, MSH3, MSH2, MLH3, or MSH1, and homologs of PMSR. 15. The method of claim 13 wherein said dominant negative allele of a mismatch repair gene comprises a dominant negative allele of a PMS2 gene. 16. The method of claim 13 further comprising inactivation of said dominant negative allele of said mismatch repair gene, thereby stabilizing the genome of said hypermutated hybridoma. 17. The method of claim 13 wherein said higher titer of said antibodies is at least about 1.5-8 fold greater than the titer produced by said parental hybridoma cell. 18. The method of claim 16 wherein said dominant negative allele of a mismatch repair gene is inactivated by knocking out said dominant negative allele or removing an inducer of said dominant negative allele. 19. The method of claim 13 wherein the dominant negative mismatch repair gene is introduced into said hybridoma cell after the fusion of said myeloma with said immunoglobulin-producing cells. 20. The method of claim 13 wherein said myeloma cells express a dominant negative mismatch repair gene which is also expressed in said hybridoma cells. 21. A method for producing mammalian expression cells that produce high-affinity antibodies from in vitro immunized immunoglobulin-producing cells comprising: (a) combining donor cells comprising immunoglobulin-producing cells with an immunogenic antigen in vitro;(b) fusing said immunoglobulin-producing cells with myeloma cells to form hybridoma cells;(c) performing a screen for binding of antibodies produced from said hybridoma cells to antigen;(d) cloning immunoglobulin genes from said hybridoma into a mammalian expression cell, wherein said mammalian expression cell expresses a dominant negative allele of a mismatch repair gene;(e) incubating said mammalian expression cell with a chemical mutagen;(f) performing a screen for mammalian expression cells that secrete antibodies with higher affinity for antigen as compared to antibodies produced from said hybridoma cells;thereby producing mammalian expression cells that produce high-affinity antibodies from in vitro immunized human immunoglobulin-producing cells. 22. The method of claim 21 wherein said dominant negative allele of a mismatch repair gene is introduced into said mammalian expression cell prior to introduction of said immunoglobulin genes. 23. The method of claim 21 wherein said dominant negative allele of a mismatch repair gene is introduced into said mammalian expression cell after introduction of said immunoglobulin genes. 24. The method of claim 21 wherein said dominant negative allele of a mismatch repair gene is introduced into said mammalian expression cell simultaneously said immunoglobulin genes. 25. The method of claim 21 wherein said mismatch repair gene is selected from the group consisting of PMS2, PMS1, PMSR3, PMSR2, PMSR6, MLH1, GTBP, MSH3, MSH2, MLH3, or MSH1, and homologs of PMSR genes. 26. The method of claim 21 wherein said dominant negative allele of a mismatch repair gene comprises a dominant negative allele of a PMS2 gene. 27. The method of claim 21 wherein said high affinity antibodies have an affinity of at least about 1×107 M−1 to about 1×1014 M−1. 28. A method for producing mammalian expression cells that produce high-affinity antibodies from in vitro immunized immunoglobulin-producing cells comprising: (a) combining donor cells comprising immunoglobulin-producing cells with an immunogenic antigen in vitro;(b) fusing said immunoglobulin-producing cells with myeloma cells to form hybridoma cells, wherein said hybridoma cells express a dominant negative allele of a mismatch repair gene;(c) incubating said hybridoma cells with a chemical mutagen;(d) incubating said hybridoma cells to allow for mutagenesis, thereby forming hypermutated hybridoma cells;(e) performing a screen for binding of antibodies to antigen for antibodies produced from said hypermutated hybridoma cells;(f) selecting hypermutated hybridoma cells that produce antibodies with greater affinity for said antigen than antibodies produced by said parental hybridoma cells;(g) cloning immunoglobulin genes from said hybridoma into a mammalian expression cell;thereby producing mammalian expression cells that produce high-affinity antibodies from in vitro immunized immunoglobulin-producing cells. 29. The method of claim 28 wherein said dominant negative allele of a mismatch repair gene is expressed in said myeloma cell and in said hybridoma cell. 30. The method of claim 28 wherein said dominant negative allele of a mismatch repair gene is introduced into said hybridoma cell after said fusion. 31. The method of claim 28 wherein said mismatch repair gene is selected from the group consisting of PMS2, PMS1, PMSR3, PMSR2, PMSR6, MLH1, GTBP, MSH3, MSH2, MLH3, or MSH1, and homologs of PMSR genes. 32. The method of claim 28 wherein said dominant negative allele of a mismatch repair gene comprises a dominant negative allele of a PMS2 gene. 33. The method of claim 28 wherein said high affinity antibodies have an affinity of at least about 1×107 M−1 to about 1×1014 M−1. 34. A method for producing mammalian expression cells that produce high titers of high-affinity antibodies from in vitro immunized immunoglobulin-producing cells comprising: (a) combining donor cells comprising immunoglobulin-producing cells with an immunogenic antigen in vitro;(b) fusing said immunoglobulin-producing cells with myeloma cells to form hybridoma cells;(c) performing a screen for binding of antibodies produced from said hybridoma cells to antigen;(d) cloning immunoglobulin genes from said hybridoma into a parental mammalian expression cell, wherein said mammalian expression cell expresses a dominant negative allele of a mismatch repair gene;(e) incubating said parental mammalian expression cell with a chemical mutagen;(f) incubating said parental mammalian expression cell to allow for mutagenesis, thereby forming hypermutated mammalian expression cells;(g) performing a screen of hypermutable mammalian expression cells that secrete antibodies with higher affinity for antigen as compared to antibodies produced from said hybridoma cells; and(h) performing a screen of hypermutable mammalian expression cells that secrete higher titers of antibodies than parental mammalian expression cells;thereby producing mammalian expression cells that produce high titers of high-affinity antibodies from in vitro immunized immunoglobulin-producing cells. 35. The method of claim 34 wherein said dominant negative allele of a mismatch repair gene is introduced into said mammalian expression cell prior to introduction of said immunoglobulin genes. 36. The method of claim 34 wherein said dominant negative allele of a mismatch repair gene is introduced into said mammalian expression cell after introduction of said immunoglobulin genes. 37. The method of claim 34 wherein said dominant negative allele of a mismatch repair gene is introduced into said mammalian expression cell simultaneously said immunoglobulin genes. 38. The method of claim 34 wherein said mismatch repair gene is selected from the group consisting of PMS2, PMS1, PMSR3, PMSR2, PMSR6, MLH1, GTBP, MSH3, MSH2, MLH3, or MSH1, and homologs of PMSR genes. 39. The method of claim 34 wherein said dominant negative allele of a mismatch repair gene comprises a dominant negative allele of a PMS2 gene. 40. The method of claim 34 wherein said high affinity antibodies have an affinity of at least about 1×107 M−1 to about 1×1014 M−1. 41. The method of claim 34 wherein said higher titer of said antibodies is at least about 1.5-8 fold greater than the titer produced by said parental hybridoma cell.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (174)
Tkachuk Zenovy (Kiev SUX) Kvasyuk Eugeny (Kiev SUX) Matsuka Gennady (Kiev SUX) Mikhailopulo Igor (Kiev SUX), (2′-5′) oligoadenylate analogues useful as inhibitors of host-v5.-graft response.
Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), 2′,5′-phosphorothioate oligoadenylates and their covalent conjugates with polylysine.
Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR) Stirchak Eugene P. (Corvallis OR), Alpha-morpholino ribonucleoside derivatives and polymers thereof.
Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Vasseur Jean J. (San Marcos CA) Debart Francoise (Montpellier FRX), Backbone modified oligonucleotide analogues.
Sanghvi Yogesh S. (San Marcos CA) Cook Phillip D. (Vista CA), Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
Ohtsuka Eiko (Sappro JPX) Inoue Hideo (Sappro JPX) Morisawa Hirokazu (Kawasaki JPX) Shibahara Susumu (Kawasaki JPX) Mukai Sachiko (Kawasaki JPX) Nishihara Tohru (Kurashiki JPX), Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and st.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), DNA-reporter conjugates linked via the 2′or 5′-primary amino group of the 5′-terminal nucleoside.
Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Exonuclease resistant terminally substituted oligonucleotides.
Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke Shee L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
Magda Darren (Cupertino CA) Sessler Jonathan L. (Austin TX) Iverson Brent L. (Austin TX) Sansom Petra I. (Austin TX) Crofts Shaun P. (Campbell CA), Method of expanded porphyrin-oligonucleotide conjugate synthesis.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA) Eder Paul S. (Iowa City IA) Dagle John M. (Iowa City IA), Methods for blocking the expression of specifically targeted genes.
Nicolaides, Nicholas C.; Grasso, Luigi; Sass, Philip M., Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics.
Grasso, Luigi; Liang, Shaohong; Nicolaides, Nicholas C.; Sass, Philip M., Methods of generating high-production of antibodies from hybridomas created by in vitro immunization.
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
Matteucci Mark (Burlingame CA) Jones Robert J. (Daly City CA) Munger John (San Francisco CA), Modified internucleoside linkages having one nitrogen and two carbon atoms.
Lin Kuei-Ying (Fremont CA) Matteucci Mark (Burlingame CA), Non-nucleoside linkers for convenient attachment of labels to oligonucleotides using standard synthetic methods.
Shizuya Hiroaki (1632 Indiana Ave. South Pasadena CA 91030) Millar Sharon L. (1825 Lanai St. West Covina CA 91792), Non-radioisotope tagging of fragments.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Nguyen Thanh T. (Tigy FRX) Helene Claude (Saint Cyr en Val FRX) Asseline Ulysse (La Source FRX), Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis a.
Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Nuclease resistant compounds.
Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
Swaminathan Sundaramoorthi ; Matteucci Mark ; Jones Robert J. ; Pudlo Jeff ; Munger John, Nuclease stable and binding competent oligomers and methods for their use.
Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA), Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled.
Buhr Chris (Daly City CA) Matteucci Mark (Burlingame CA) Bischofberger Norbert W. (San Carlos CA) Froehler Brian (Belmont CA), Nucleoside 5′-methylene phosphonates.
Froehler Brian C. (Belmont CA) Buhr Chris A. (Daly City CA), Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues.
Klevan Leonard (Washington DC) Gebeyehu Gulilat (Silver Spring MD) Rao Prasad Y. (Damascus MD), Nucleotide analogs for nucleic acid labeling and detection.
Meyer ; Jr. Rich B. (Woodinville WA) Adams A. David (Snohomish WA) Petrie Charles R. (Woodinville WA), Oligo (aa
상세보기
Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
Bischofberger Norbert (San Carlos CA) Kent Ken (Mountain View CA) Wagner Rick (Burlingame CA) Buhr Chris (Daly City CA) Lin Kuei-Ying (Fremont CA), Oligonucleotide analogs capable of passive cell membrane permeation.
Weis Alexander Ludvik (Berwyn PA) Hausheer Frederick Herman (San Antonio TX) Chaturvedula Prasad Venkata Chala (Exton PA) Delecki Daniel Joseph (Radnor PA) Cavanaugh ; Jr. Paul Francis (West Chester , Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleo.
Warren ; III Harold C. (Rush NY) Oakes Fred T. (Rochester NY), Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction proce.
Haralambidis Jim (Box Hill South AUX) Tregear Geoffrey W. (Hawthorn AUX), Oligonucleotide-polyamide conjugates and methods of production and applications of the same.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
Imbach Jean-Louis (Montpellier FRX) Gosselin Gilles J. M. (Montpellier FRX), Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
Meyer ; Jr. Rich B. (Woodinville WA) Gall Alexander A. (Bothell WA) Reed Michael W. (Seattle WA), Peptide linkers for improved oligonucleotide delivery.
Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
Maddry Joseph A. (Birmingham AL) Reynolds Robert C. (Birmingham AL) Secrist John A. (Birmingham AL) Montgomery John A. (Birmingham AL) Crooks Peter A. (Lexington KY), Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages.
Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
Gordon Julian (307 E. Sheridan Rd. Lake Bluft IL 60044) Minks Michael A. (Biochemistry Dept. ; University of the Witwatersrand ; 1 Jan Smuts Ave Johannesburg 2001 ZAX), Specific antibody to the native form of 2′5′-oligonucleotides, the method of preparation and the use as reagents in im.
Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA), Texaphyrin metal complexes having improved functionalization.
Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA) Kral Vladimir A. (Austin TX) Magda Darren (Cupertino CA), Texaphyrin-oligonucleotide conjugates.
Reed Michael W. (3575 NE. 180th Seattle WA 98105) Meyer ; Jr. Rich B. (15411 NE. 176th Pl. Woodinville WA 98072), Trifunctional intermediates for preparing 3′-tailed oligonucleotides.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.